Relaxo delivered a strong Q4 with net profit reaching ₹67.7 Crore and revenue climbing to ₹751.1 Crore. The board recommended a final dividend of ₹3.50 per share, reflecting confidence in its cash flow and strategic pivot toward premium footwear segments.
Market snapshot: Relaxo Footwears Limited has reported a robust financial performance for the final quarter of FY26, characterized by significant bottom-line expansion and steady revenue growth. The company successfully navigated a competitive landscape by leveraging premiumization and operational efficiencies, leading to a 20.4% jump in net profit.
Relaxo's ability to maintain 20%+ profit growth despite a single-digit revenue increase indicates a structural shift in its product mix. By focusing on higher-margin sub-brands like Sparx and Flite and utilizing its new 30-acre Bhiwadi capacity, the company is positioning itself to capture a larger share of the organized footwear retail market which is currently benefiting from favorable GST shifts for products under ₹2,500.
The results suggest a broader recovery in the consumer discretionary sector, specifically in mass-premium footwear. Positive volume growth and margin expansion signal that Relaxo is successfully defending its market share against unorganized players. This provides a positive capital allocation signal for investors focused on stable, high-volume manufacturing with improving profitability profiles.
Market Bias: Bullish
Profit growth of 20.4% significantly exceeding revenue growth of 8.0% indicates high operational leverage and successful premiumization. A final dividend of ₹3.50 adds yield support.
Overweight: Consumer Discretionary, Footwear, Specialty Retail
Underweight: Raw Material (Rubber/EVA) Suppliers
Trigger Factors:
Time Horizon: Near-term (0-3 months)
The Indian footwear industry is undergoing a shift from unorganized to organized retail, accelerated by GST adjustments and quality standards (BIS). Relaxo, as the largest manufacturer by volume, is capitalizing on this by expanding its retail footprint (Relaxo Parivaar app reaching 70k+ outlets) and diversifying into the high-growth sports and athleisure categories.
In December 2023, Relaxo acquired 30 acres in Bhiwadi for ₹135 Crore to support long-term capacity expansion. More recently, the company launched its Spring Summer 2026 lineup featuring 250+ styles, focusing on lightweight and comfort-led designs for both metro and non-metro markets.
Relaxo has proven that even in a challenging demand environment, a focus on brand-led premiumization and cost discipline can drive superior bottom-line results. The FY26 exit sets a strong foundation for volume-led growth in the coming fiscal year.
The profit surge was driven by a mix of 8% revenue growth and significant improvements in operational efficiencies. Successful cost management and a strategic shift towards higher-margin premium products like Sparx helped expand margins.
The dividend represents a 350% payout on the face value of shares. This recommendation indicates the company's strong cash position and its commitment to returning value to shareholders following a steady fiscal year.
Yes, the shift from 12% to 5% GST on mid-range footwear improves Relaxo's price competitiveness against unorganized players. This regulatory change is expected to drive higher volumes in the organized mass and mid-market segments.
High Performance Trading with SAHI.
Related
JPMorgan Downgrades Apollo Tyres: Navigating Commodity Headwinds and Sector Re-rating
JPMorgan Bullish on TVS Motor: Target Price Hiked to ₹4,440 as Resilience Outshines Sector Risks
JPMorgan Shifts Stance on Escorts Kubota: Upgrade to Neutral Amid Sector Recalibration
Geopolitical Friction in Hormuz: Oil Majors Flag Costs of Proposed Tolls and India’s Readiness Gaps
Recent
Sical Logistics Q4 Revenue Climbs to ₹105 Cr as Losses Surge 300% YoY
Swan Energy Q4 Profit Hits ₹268 Crore Reversing Year-Ago Loss of ₹17.7 Crore
Regulatory Curbs Drive 21% Profit Decline in Diversified Financial Services Sector
Peninsula Land Q4 Revenue Falls to ₹40.2 Crore; Net Loss Surges to ₹118 Crore
Concord Biotech Q4 Net Profit Sinks 35% to ₹90 Cr as Revenues Decline